Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To determine the time to efficacy onset of glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40).
Methods: This post hoc analysis of data from the 1-year, double-blind, placebo-controlled phase of the Glatiramer Acetate Low-Frequency Administration study (NCT01067521) of GA40 in patients with relapsing-remitting MS (RRMS) sought to determine the timing of efficacy onset using a novel data-censoring approach.
Results: Compared with placebo-treated patients, those receiving GA40 exhibited a >30% reduction in the accumulated annualized relapse rate (ARR) within 2 months of initiating treatment and generally sustained this treatment difference during the 1-year study. Similarly, the proportion of GA40-treated patients who remained relapse-free was distinctly greater by month 2 and continued to increase up to a 10.8% difference at the end of the study. In addition, GA40 treatment was associated with a significant reduction in the number of gadolinium-enhancing T1 lesions and new/enlarging T2 lesions by month 6, with full treatment effect observed after 1 year.
Conclusions: GA40 contributes to efficacy within 2 months of the start of treatment in patients with RRMS. These results are consistent with the observed time to efficacy onset for patients treated with GA 20 mg/mL daily in previous randomized, placebo-controlled clinical trials.
Classification Of Evidence: This study provides Class II evidence that for patients with RRMS, a 3-times-weekly formulation of GA 40 mg/mL leads to a >30% reduction in the ARR within 2 months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299631 | PMC |
| http://dx.doi.org/10.1212/NXI.0000000000000327 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
J Neurol Neurosurg Psychiatry
September 2025
Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation, Bron, France.
Unlabelled: BackgroundTarget trial emulation (TTE) offers a formal framework for causal inference using observational data, but its validity must be evaluated in each research domain by replicating randomised clinical trials (RCTs). We aimed to replicate eight RCTs evaluating the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) using French registry data.
Methods: This multicentre, retrospective, observational study was conducted using data extracted in December 2023 from the (OFSEP) database.
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
Mult Scler
September 2025
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA; Population Health Outcomes and Pharmacoepidemiology Education and Research (P-HOPER Center), University of Houston College of Pharmacy, Houston, TX, USA.
Background: With advances in disease-modifying therapies (DMTs), patients with multiple sclerosis (MS) are living longer.
Objective: This study examined MS prevalence and DMT use among older adults 65 years and above in the United States.
Methods: The study analyzed 2011-2021 Medicare fee-for-service claims data.
Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US.
JAMA Health Forum
August 2025
Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
Importance: Brand-name drugs in the US are sold at high prices during market exclusivity periods defined by their patents, before prices are lowered by generic competition. Drug manufacturers use several strategies to extend these market exclusivity periods and delay generic competition, including obtaining overlapping thickets of patents.
Objective: To estimate excess US spending associated with delays in generic competition due to extended market exclusivity for 4 top-selling drugs.
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score.
Mult Scler Relat Disord
August 2025
Department of Neurology, Medical University of Innsbruck, Austria. Electronic address:
Objective: To investigate whether the VIAADISC score predicts disease reactivation in relapsing multiple sclerosis (RMS) after de-escalation/discontinuation of disease-modifying-therapy (DMT) METHODS: We included RMS patients who i) received any DMT other than interferon-beta or glatiramer-acetate ≥12 months, ii) de-escalated/discontinued DMT, iii) had MRI before de-escalation/discontinuation, and iv) had ≥12 months of follow-up. VIAADISC score (0-6; age <45/45-54/≥55 = 2/1/0 points, MRI activity = 2 points, duration without clinical disease activity <4/4-8/>8 years = 2/1/0 points) was calculated. The primary endpoint was disease reactivation (relapse and/or disability progression).
View Article and Find Full Text PDFBeyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment.
Neurol Ther
August 2025
Department of Neurology, Hospital Universitario de Vigo, Complexo Hospitalario Universitario de Vigo (CHUVI), Pontevedra, Galicia, Spain.
Introduction: Injectable drugs, including interferon-beta and glatiramer acetate (collectively referred to as BRACE), dimethyl fumarate (DMF), and teriflunomide (TER) are commonly used as initial disease-modifying therapies (DMTs) for multiple sclerosis (MS), especially in patients with favorable prognostic profiles. Despite their continued use, real-world comparative data on long-term treatment persistence and comprehensive disease control remain limited.
Methods: This retrospective study analyzed 400 patients initiating BRACE (n = 132), DMF (n = 130), or TER (n = 138) between 2014 and 2024 in routine clinical practice.